切换到干粉吸入器:通过更低的碳足迹来控制疾病
Christer Janson1, Hanna Hisinger-Mölkänen2, Lilla Tamasi3
1Respiratory, Allergy and Sleep Research, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Pulmonary therapy
|October 6, 2025
概括
从压力计量剂量吸入器 (pMDIs) 转换为干粉吸入器 (DPIs),可以保持喘和COPD的控制,同时显著减少对环境的影响. 这种转变可以大幅减少碳足迹,而不会影响患者的治疗结果.
科学领域:
- 环境科学 环境科学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 压力计量剂量吸入器 (pMDIs) 的碳足迹明显高于干粉吸入器 (DPIs).
- 医疗保健专业人员担心,在切换吸入器类型时,可能对喘和COPD治疗结果产生负面影响.
研究的目的:
- 评估与将吸入器治疗从pMDIs转换为DPIs相关的患者结果和碳足迹.
- 评估过渡喘和COPD患者的临床疗效和环境效益,以治疗布德尼德-形式醇Easyhaler DPI.
主要方法:
- 一项为期12周的现实研究后期分析,涉及患有喘或COPD的成年患者,这些患者从pMDIs转换为budesonide-formoterol Easyhaler DPI.
- 分析了临床结果,包括喘控制测试 (ACT),迷你喘生活质量问卷 (Mini-AQLQ),肺功能,缓解剂使用 (喘),COPD评估测试 (CAT) 和修改的医学研究委员会呼吸障碍量表 (mMRC) (COPD).
- 碳足迹计算是基于pMDIs和DPIs的既定估计.
主要成果:
- 在切换到DPI后,所有测量的临床结果参数都显示出显著改善 (p < 0.001).
- 在喘患者中,缓解药物的使用显著下降 (p < 0.001).
- 与pMDIs相比,DPI对维持治疗患者的估计年碳排放量较DPI低97.0%,而喘缓解药物的减少甚至更大 (99.6%).
结论:
- 从pMDIs转换为DPIs有效地保持了喘和COPD患者的疾病控制.
- 这种转变导致吸入器治疗的碳足迹大幅减少,与环境可持续性目标保持一致.
相关概念视频
01:23Inhaled Medications
746
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
746
01:26COPD: Management Using Bronchodilators and Corticosteroids
726
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
726
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K